Replies to post #59214 on Biotech Values

[zipjet]

DD,

I know what I said and I would not retract a single word of it.

Copaxone wins against the Ifn's in the long run.

But Tysabri looks like a much better drug provided it does not get knocked out of the running by PML or other issues. Rituxan also looks like a contender - to my read even better than T. It will need more studies. They will need to determine the optimum dosing approach which could boost the results. Even then R's results may not hold up.

Five years is a long time. We do not know what the field of drugs will look like then.

My statements are consistent.

ij